Andreas MD - Xvivo Perfusion Chief Officer

XVIVO Stock

SEK 480.00 7.50 1.59%

Insider

Andreas MD is Chief Officer of Xvivo Perfusion AB

Age	46
Phone	46 3 17 88 21 50
Web	https://www.xvivoperfusion.com

Xvivo Perfusion Management Efficiency

Xvivo Perfusion's management efficiency ratios could be used to measure how well Xvivo Perfusion manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Xvivo Perfusion to Peers

Predict price of Xvivo Perfusion

Xvivo Perfusion AB has accumulated 1.52 M in total debt with debt to equity ratio (D/E) of 1.2, which is about average as compared to similar companies. Xvivo Perfusion AB has a current ratio of 4.6, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Xvivo Perfusion until it has trouble settling it off, either with new capital or with free cash flow. So, Xvivo Perfusion's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Xvivo Perfusion AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Xvivo to invest in growth at high rates of return. When we think about Xvivo Perfusion's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Urban Strindlov	CellaVision AB	59
	James Ewing	Invisio Communications AB	N/A
	Johanna Flting	BioArctic AB	51
	Oskar Bosson	BioArctic AB	47
	Frida Lekander	BioArctic AB	N/A
	Ricardo Capella	Vitrolife AB	55
	Pr Gellerfors	BioArctic AB	76
	Tina Lawesson	Invisio Communications AB	55
	Gunilla Osswald	BioArctic AB	62
	Christian Priess	Hexatronic Group AB	53
	Gunilla Andersson	BioArctic AB	62
	Michael Peterson	Invisio Communications AB	58
	Thomas Andersen	Hexatronic Group AB	49
	Tomas Jendel	Hexatronic Group AB	50
	Harald Borgeke	BioArctic AB	N/A
	Simon Ostergaard	CellaVision AB	52
	Hkan Bckstrm	Hexatronic Group AB	57
	Jan Mattsson	BioArctic AB	63
	Daniel Forss	Vitrolife AB	51
	Henrik LarssonLyon	Hexatronic Group AB	57
	Pernilla Linden	Hexatronic Group AB	54

Xvivo Perfusion AB , a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. Xvivo Perfusion AB was founded in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in Sweden and is traded on Stockholm Stock Exchange. It employs 45 people. Xvivo Perfusion AB (XVIVO) is traded on Stockholm Exchange in Sweden and employs 133 people.

Management Performance

	Return On Equity	0.0136
	Return On Asset	0.0057

Xvivo Perfusion AB Leadership Team

Elected by the shareholders, the Xvivo Perfusion's board of directors comprises two types of representatives: Xvivo Perfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xvivo. The board's role is to monitor Xvivo Perfusion's management team and ensure that shareholders' interests are well served. Xvivo Perfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xvivo Perfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Jaya Tiwari, VP Affairs
	Magnus Nilsson, CEO and Director
	Katrin Gisselfalt, Global Director
	Charlotte Walldal, Global director
	Lena BSc, Chief Officer
	Andreas MD, Chief Officer
	Johan Holmstrom, Chief Officer
	Christoffer Rosenblad, Acting Officer
	Christer Flon, Global Head of Marketing and Sales and Global Marketing and Sales Director
	Kristoffer Nordstrom, CFO Relations

Xvivo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xvivo Perfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	0.0136
	Return On Asset	0.0057
	Profit Margin	0.04 %
	Operating Margin	0.04 %
	Current Valuation	5.54 B
	Shares Outstanding	29.83 M
	Shares Owned By Insiders	12.25 %
	Shares Owned By Institutions	54.00 %
	Price To Earning	662.55 X
	Price To Book	4.23 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Xvivo Stock Analysis

When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC